Napredna pretraga

Pregled bibliografske jedinice broj: 890070

Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients


Ozretić, Petar; Alvir, Ilija; Šarčević, Božena; Vujašković, Željko; Rendić-Miočević, Zrinka; Roguljić, Ana; Beketić-Orešković, Lidija
Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients // International journal of biological markers, 33 (2018), 1; 109-115 doi:10.5301/ijbm.5000291 (međunarodna recenzija, članak, znanstveni)


Naslov
Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients

Autori
Ozretić, Petar ; Alvir, Ilija ; Šarčević, Božena ; Vujašković, Željko ; Rendić-Miočević, Zrinka ; Roguljić, Ana ; Beketić-Orešković, Lidija

Izvornik
International journal of biological markers (0393-6155) 33 (2018), 1; 109-115

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
B-cell lymphoma 2 ; Carbonic anhydrase IX ; Ki-67 antigen ; Triple-negative breast neoplasms ; Tumor biomarkers ; Tumor suppressor protein p53

Sažetak
Background: The objective of this study was to examine the prognostic significance of carbonic anhydrase IX (CAIX), an endogenous marker for tumor hypoxia ; cellular tumor antigen p53, and apoptosis regulator Bcl-2 in triple-negative breast cancer (TNBC) patients. Methods: Immunohistochemically determined expression of CAIX, p53, Bcl-2 and proliferation factor Ki-67, analyzed on sixty-four paraffin-embedded TNBC tissue samples, was used to assess their relation to clinicopathologic variables and prognostic implication on overall survival (OS). Results: Bcl-2 expression was negatively correlated with histological grade of tumor, while expression of p53 was positively correlated with the same clinical variable (P = 0.036 and P = 0.033, respectively). The p53 expression was also positively correlated with tumor size (P = 0.010). Survival analysis showed that patients with high Bcl-2 expression (above cut-off value determined by ROC curve analysis) have shorter OS (P = 0.020). The same was observed for patients with tumors larger than 5 cm (P = 0.034) or positive lymph nodes (P = 0.004). Among all three examined markers, multivariate analysis showed that only Bcl-2 expression was strong independent prognostic indicator for decreased OS (HR 10.45, 95% CI 2.229–49.022, P = 0.003). Conclusions: Elevated expression of Bcl-2 was an independent prognostic factor for poorer OS in TNBC and as such a significant marker for tumor aggressiveness.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti



POVEZANOST RADA


Projekt / tema
074-0982464-1187 - KLINIČKO ZNAČENJE TUMORSKE HIPOKSIJE U BOLESNIKA LIJEČENIH RADIOTERAPIJOM (Lidija Beketić-Orešković, )

Ustanove
Klinika za tumore,
Institut "Ruđer Bošković", Zagreb,
Medicinski fakultet, Zagreb

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati